About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Metformin for Weight Loss in Schizophrenia | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDNANCT01177709

Metformin for Weight Loss in Schizophrenia

Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.

Lead sponsor: Nathan Kline Institute for Psychiatric Research•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Nathan Kline Institute for Psychiatric Research

Patients who had gained more than 10 lbs of weight in the last 3 months or had BMI of 35 or greater were treated with metformin up to 2500 mg/day in an open label study of up to 3 months time. Changes in weight and glucose measures were recorded.

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients will be 18-70 years of age;
•Currently hospitalized or an outpatient at MPC;
•BMI ≥ 35 or excessive recent weight gain ( \> than 10 lb weight gain in the past 3 months);
•Patients will have a diagnosis of schizophrenia or schizoaffective disorder or bipolar disorder.

Exclusion Criteria

•Age below 18 or over 70;
•Patient is currently already treated with metformin.

Related studies

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

NCT05545306 · Obesity, Normal Physiology, and more

A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

NCT04453072 · Obesity, Malignant Neoplasm

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

NCT07187830 · Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight

Can Pre-operative Lean Mass Predict Weight Loss After Roux-en-Y Gastric Bypass?

NCT07565051 · Morbid Obesity Requiring Bariatric Surgery

Pregnancy Exercise Mode Effect on Childhood Obesity

NCT04805502 · Pregnancy, Overweight and Obesity

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 1, 2017Terms

Trial snapshot

StatusTERMINATED

PhaseNA

Enrollment12

Start dateMay 2008

Last updatedSep 1, 2017

Condition

Schizophrenia Obesity

Locations shown

Manhatan Psychiatric Center

New York, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 1, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions